Stockscreener 앱 받기
1.96
2.97%
-0.06
시간 외 거래:
2.03
0.07
+3.57%
전일 마감가:
$2.02
열려 있는:
$2.02
하루 거래량:
9,699
Relative Volume:
0.40
시가총액:
$3.14M
수익:
-
순이익/손실:
$-36.46M
주가수익비율:
-12.25
EPS:
-0.16
순현금흐름:
$-30.20M
1주 성능:
+3.16%
1개월 성능:
-7.98%
6개월 성능:
-68.49%
1년 성능:
-75.11%
1일 변동 폭
$1.95
$2.04
1주일 범위
$1.63
$2.1319
52주 변동 폭
$1.63
$32.85
Alaunos Therapeutics Inc Stock (TCRT) Company Profile
명칭
Alaunos Therapeutics Inc
전화
(346) 355-4099
주소
2617 BISSONNET ST, HOUSTON
TCRT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TCRT
Alaunos Therapeutics Inc
|
1.96 | 3.14M | 0 | -36.46M | -30.20M | -2.40 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Alaunos Therapeutics Inc Stock (TCRT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2022-10-04 | 재개 | Wells Fargo | Overweight |
Alaunos Therapeutics Inc 주식(TCRT)의 최신 뉴스
TCRT stock touches 52-week low at $1.92 amid market challenges - Investing.com
Alaunos Therapeutics Inc (TCRT) Quarterly 10-Q Report - Quartzy
Ziopharm: Q3 Earnings Snapshot - The Washington Post
TCRT Stock Touches 52-Week Low at $1.96 Amid Market Challenges - Investing.com Nigeria
TCRT stock touches 52-week low at $2.06 amid market challenges - Investing.com
Intracranial Therapeutic Market Rewriting its Growth Cycle |Novartis AG, BioMarin, CORESTEM Inc., Alaunos Therapeutics, – IndiaPolitics.com - IndiaPolitics.com
After axing its sole clinical prospect last year, Alaunos cuts ties with Precigen - Fierce Biotech
Alaunos Therapeutics ends key agreement and updates on financial condition By Investing.com - Investing.com Australia
Alaunos Therapeutics Ends Licensing Deal, Reassesses Strategy - Yahoo Finance
Precigen reclaims rights after terminating license agreement - Investing.com India
Precigen Terminates License Agreement With Alaunos Therapeutics - MarketWatch
Alaunos Therapeutics ends key agreement and updates on financial condition - Investing.com
Genentech buys Regor’s CDK inhibitors in $850m deal - Clinical Trials Arena
AskBio and Belief BioMed partner to advance gene therapies - Pharmaceutical Technology
Applied Therapeutics: AdCom Decision Takes Govorestat Approval A Step Closer (NASDAQ:APLT) - Seeking Alpha
An Analysis of Atricure Inc (ATRC)’s Potential Price Growth - Knox Daily
Applied Therapeutics Surges on Positive FDA Update for Govorestat - BP Journal
Applied Therapeutics jumps as US FDA cancels panel meeting for genetic disorder drug - XM
Gene Switch / Molecular Switch Market Set to Reach USD 1.44 Billion by 2031 with 9.9% CAGR - WhaTech
Daily Market Movement: Atricure Inc (ATRC) Sees a -3.23 Decrease, Closing at 27.30 - The Dwinnex
Aptevo Therapeutics announces $3.0M offering priced at-the-market - TipRanks
Check out these key findings about Atricure Inc (ATRC) - SETE News
Atmos Energy Co. (NYSE:ATO) Shares Sold by Prudential PLC - MarketBeat
Gilead and Genesis partner to create novel therapies using AI - Pharmaceutical Technology
Navigator gains $100m in Series A funding for antibody therapeutics - Pharmaceutical Technology
VION Biosciences acquires Echelon Biosciences - Pharmaceutical Technology
TCRT stock touches 52-week low at $2.28 amid market challenges - Investing.com India
Ziopharm: Q2 Earnings Snapshot - San Antonio Express-News
Eli Lilly inaugurates R&D facility in Boston, US - Pharmaceutical Technology
Alaunos Therapeutics (NASDAQ:TCRT) Trading Down 4.2% - Defense World
Genentech and Sangamo to develop neurodegenerative disease therapies - Pharmaceutical Technology
TCRT stock touches 52-week low at $3.57 amid market challenges - Investing.com Nigeria
Alaunos Therapeutics announces 1-for-10 reverse stock split By Investing.com - Investing.com Australia
Alaunos Therapeutics announces 1-for-10 reverse stock split - Investing.com
XyloCor taps SmartWise’s infusion device for gene therapy administration - Clinical Trials Arena
Intracranial Therapeutic Industry Startegy Analysis} Novartis AG, BioMarin, CORESTEM Inc., Alaunos Therapeutics ... - Economica
Alaunos (TCRT) Dips More Than Broader Markets: What You Should Know - Yahoo New Zealand News
Zacks Industry Outlook Highlights Dyne Therapeutics, Silence Therapeutics, Alaunos Therapeutics, Assertio Holdings ... - Yahoo Lifestyle UK
Alaunos Therapeutics appoints new accounting firmInvesting.com ZA - Investing.com South Africa
Alaunos Therapeutics appoints new accounting firm By Investing.com - Investing.com
Ziopharm Oncology to Participate in Upcoming Conferences - Quantisnow
Ziopharm Oncology to Report Fourth Quarter and Full Year 2020 Financial Results and Host Webcast on February 25 ... - Quantisnow
Alaunos Therapeutics Appoints Abhishek Srivastava, Ph.D. as Vice President, Technical Operations - Quantisnow
Turn Bio and HanAll to develop therapies for age-related conditions - Pharmaceutical Technology
AltruBio secures $225m for immune checkpoint programme development - Pharmaceutical Technology
Avenzo Therapeutics secures $150m to bolster oncology pipeline - Pharmaceutical Technology
Gilead concludes acquisition of CymaBay Therapeutics for $4.3bn - Pharmaceutical Technology
Alaunos Therapeutics Inc (TCRT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.88%
2.65%
자본화:
|
볼륨(24시간):